{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shumbayawonda E"],"funding":["EC | Horizon 2020 Framework Programme","EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)"],"pagination":["74"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11920111"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(1)"],"pubmed_abstract":["<h4>Background</h4>Increasing prevalence of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) poses a growing healthcare burden. Noninvasive diagnostic tools to replace liver biopsy are urgently needed. We investigated the utility and cost-effectiveness of including multiparametric magnetic resonance imaging (mpMRI) to the management of adults with suspected MASLD multi-nationally.<h4>Methods</h4>RADIcAL-1, a 1:1 randomised controlled trial (standard-of-care [SoC] vs. imaging arm [IA; SoC+mpMRI]) included 802 participants from Germany, Netherlands, Portugal and UK. Wilcoxon-rank tests were used to compare access to healthcare practitioners, patient assessments and proportion of patients with a diagnosis (%diagnosis). Liver fa"],"journal":["Communications medicine"],"pubmed_title":["Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial."],"pmcid":["PMC11920111"],"funding_grant_id":["719445"],"pubmed_authors":["Banerjee R","Lorgelly P","Carolan JE","Cuthbertson DJ","French M","Beyer C","Byrne CD","Barclay S","Forton D","Agarwal K","Fraser A","Backhus J","Miller MH","Castelo Branco M","Coenraad MJ","Lamb HJ","Tonev D","Ajaz S","Shumbayawonda E","Schaapman JJ","Patel J","Dollinger MM"],"additional_accession":[]},"is_claimable":false,"name":"Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial.","description":"<h4>Background</h4>Increasing prevalence of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) poses a growing healthcare burden. Noninvasive diagnostic tools to replace liver biopsy are urgently needed. We investigated the utility and cost-effectiveness of including multiparametric magnetic resonance imaging (mpMRI) to the management of adults with suspected MASLD multi-nationally.<h4>Methods</h4>RADIcAL-1, a 1:1 randomised controlled trial (standard-of-care [SoC] vs. imaging arm [IA; SoC+mpMRI]) included 802 participants from Germany, Netherlands, Portugal and UK. Wilcoxon-rank tests were used to compare access to healthcare practitioners, patient assessments and proportion of patients with a diagnosis (%diagnosis). Liver fa","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-01T10:11:39.589Z","creation":"2025-04-04T14:47:39.947Z"},"accession":"S-EPMC11920111","cross_references":{"pubmed":["40102528"],"doi":["10.1038/s43856-025-00796-9"]}}